Ivabradina Aurovitas

Ivabradine, the active ingredient in Ivabradina Aurovitas, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Aurovitas acts on the cardiac If current to manage conditions where heart‑rate reduction is therapeutic.

- Chronic stable angina: decreases frequency of angina attacks by lowering myocardial oxygen demand. - Heart failure with reduced ejection fraction: improves symptoms and reduces hospitalization risk through heart‑rate control. - Ischemic heart disease: alleviates chest pain by reducing cardiac workload.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: heart rate below 50 bpm. - Headache. - Dizziness. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - Persistent visual impairment. - Hepatic dysfunction. - Allergic reactions including rash or angioedema.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors. - Cardiac monitoring: obtain baseline heart rate and ECG. - Concomitant beta‑blockers: assess for excessive bradycardia. - Severe hepatic impairment: use with caution or avoid. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - CYP3A4 inhibitors: monitor for increased exposure. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Ivabradina Aurovitas may interact with several drug classes.

Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise ivabradine levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Other bradycardic agents (beta‑blockers, digoxin, amiodarone): risk of severe bradycardia. - Concomitant ivabradine with verapamil or diltiazem: can cause marked heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Calcium channel blockers (verapamil, diltiazem): may modestly increase ivabradine exposure. - Antidepressants (fluoxetine, paroxetine): potential CYP3A4 inhibition. - Antihypertensives (ACE inhibitors, ARBs): monitor blood pressure and heart rate. - Diuretics: watch for electrolyte shifts that could affect cardiac conduction.